about
Regulation generation: the suppressive functions of human regulatory T cellsThe role of regulatory T cells in cancer immunologyMyeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implicationsMolecular mimics of the tumour antigen MUC1Anti-inflammatory T-cell shift in neuropathic pain.Disrupted TH17/Treg balance in patients with chronic low back pain.Control of the inflammatory response mechanisms mediated by natural and induced regulatory T-cells in HCV-, HTLV-1-, and EBV-associated cancers.The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway.Morphoproteomic-Guided Host-Directed Therapy for Tuberculosis.COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.Gut microbiota and the paradox of cancer immunotherapyInduced and natural regulatory T cells in human cancer.Immune classification of colorectal cancer patients: impressive but how complete?Gut immune system and oral tolerance.Therapeutic cancer vaccines: a long and winding road to success.Extracellular adenosine metabolism in immune cells in melanoma.Induced regulatory T cells in inhibitory microenvironments created by cancer.A perspective on new immune adjuvant principles: Reprogramming inflammatory states to permit clearance of cancer cells and other age-associated cellular pathologiesDecreased frequency of CD73+CD8+ T cells of HIV-infected patients correlates with immune activation and T cell exhaustion.Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome.Effect of intra-tumoral magnetic nanoparticle hyperthermia and viral nanoparticle immunogenicity on primary and metastatic cancer.Hypo-fractionated Radiation, Magnetic Nanoparticle Hyperthermia and a Viral Immunotherapy Treatment of Spontaneous Canine Cancer.Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial)
P2860
Q26823216-497F1BF4-1D65-4A5B-B453-24BCB2494529Q27006663-1B6469E0-7F42-4047-8650-814D45F22780Q27014189-F7372A11-CA7E-49AC-9A44-4B83B3B0DBB6Q28485169-46D0EDEA-CDB7-4C9C-97BA-7CB19A4733CCQ30420222-38ED5D05-AD1D-4EB4-A264-6025737A3CF6Q30432801-7F0A9E82-3CFB-4A06-A9E5-3E2BF049E996Q34708248-2380C2B4-3C95-4A07-A04B-032F6696C3DAQ36075960-AB63C824-FC84-4927-B21D-B9268F8322FAQ37619959-DD7C26A3-361F-4929-A3D1-CE5DE70B04BDQ37663388-BA6FB99B-D569-4710-BF2D-FB24EAD7F10AQ37700223-5566EA70-A9B2-4A1F-9EF3-37A1F7CE395AQ38030976-C9024D5C-9BC5-46DD-B982-3FBC7580FE55Q38071673-5797EAE2-82D5-4E49-8306-9FF95D10CAA4Q38077631-ADBD3C43-7669-41EE-9A64-E2ECC1DC4DADQ38162261-D526F629-3A05-4D5B-ACFD-6487519B6D07Q38206399-C44DFDAA-248A-4315-AAD1-22DEF0789E20Q38220701-001CC8D5-80DB-46CB-931F-17B23471F58CQ41475130-2785223E-3829-4793-A769-121CE51FB08BQ42261525-6BCDE883-CE7C-4C05-96C6-F948AE968D8DQ46248185-B1B543A4-F460-433B-B2B0-B2937D570BE8Q46311025-E4ED32C0-9FC0-41D5-B44D-D1BF8E4B885FQ47331772-A06BF465-85F9-4474-A74F-F5F2BF9EC4D6Q56523838-9D9DA858-E11E-4F5C-80DB-1B7CDD3162A2
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Disarming suppressor cells to improve immunotherapy.
@en
Disarming suppressor cells to improve immunotherapy.
@nl
type
label
Disarming suppressor cells to improve immunotherapy.
@en
Disarming suppressor cells to improve immunotherapy.
@nl
prefLabel
Disarming suppressor cells to improve immunotherapy.
@en
Disarming suppressor cells to improve immunotherapy.
@nl
P2860
P1476
Disarming suppressor cells to improve immunotherapy.
@en
P2093
Theresa L Whiteside
P2860
P2888
P304
P356
10.1007/S00262-011-1171-7
P577
2011-12-07T00:00:00Z